Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FNA-based hepatic pharmacokinetics study of MK-7009 in chronic hepatitis C
NL-OMON37067Withdrawn
- Sponsor
- Merck & Co.
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of vaniprevir in hepatitis C virus infection (3 arms), sponsored by Merck & Co. Primary endpoints: Probability of successful FNA liver tissue acquisition for drug concentration assessment, MK-7009 liver concentrations at 3, 12, and 24 hours post-dose by FNA and 7 more. Planned start Sep 2012; status: withdrawn.
02
Drugs
vaniprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON37067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37067.